Nonmyeloablative allogeneic stem cell transplantation (NST) has emerged as a promising alternative to conventional allografting, due to reduced regimen-related toxicity. A variety of reduced-intensity regimens for allografting has been explored with the goal of inducing curative graftversus-tumor (GVT) responses. 1 Preliminary results have suggested that CML, CLL and idolent lymphomas may respond well to this strategy. 1 A minimally intensive approach was developed, employing low-dose TBI, CsA and MMF. 2 Fludarabine was subsequently added to decrease the risk of graft rejection. Fludarabine/TBI has been associated with low graft rejection rates after HLAidentical sibling transplants, and has been employed successfully using unrelated donors, 3 a setting where increased rejection risk has been documented after myeloablative allografting.
Since little or no cytoreduction is achieved with fludarabine/TBI, the antitumor effect relies almost entirely on the chimerism-mediated GVT effect. Post-transplant DLI may be required to enhance GVT. 1 The immune effect exerted by donor T cells often does not achieve rapid tumor responses and, while it can effectively treat indolent malignancies, control of aggressive disease may need alternative therapies. 1 Early administration of polychemotherapy poses the potential hazard of damaging the recently infused stem cells, compromising engraftment. We report here a case of intensive chemotherapy used to treat early life-threatening progression after a NST for CLL, without loss of engraftment.
Case report
The patient was a 51-year-old male diagnosed with CLL with trisomy 12, Rai stage 0 in 1997. After disease progression and treatment with 10 cycles of fludarabine-based chemotherapy without major response, he was evaluated for allogeneic transplantation. The patient had widespread bulky lymphadenopathy, and total replacement of his bone marrow (BM) by CLL. Absolute neutrophil and lymphocyte counts were 0 and 43 000/l, respectively, and he was platelet and red cell transfusion-dependent. There were no HLA-matched siblings, and he elected to undergo a NST from an unrelated donor identified by the NMDP. The donor was HLA-matched (serologically at A and B, and molecularly at C, DRB1, and DQB1), ABO-and sexmatched. Prior to transplant, debulking radiotherapy (2160 cGy) was delivered to peripheral lymphadenopathy. + cells/kg, were infused on day 0. Planned immunosuppression consisted of CsA at 1.5 mg/kg i.v. twice daily, from day −1 to day +100, then tapered to day +180, and MMF at 15 mg/kg p.o. twice daily, from day 0 to +40, then tapered to day +96. Antimicrobial prophylaxis included levofloxacin, acyclovir, inhaled pentamidine and liposomal amphotericin-B. The immediate post-transplant course was complicated by increasing hypoxia, pulmonary infiltrates, progressive mediastinal lymphadenopathy, and increasing peripheral lymphocyte and smudge cell counts, without evi-dence of cardiac failure. A transbronchial biopsy was diagnostic of CLL involvement. Additionally, lower airway colonization with Aspergillus was noticed. In an initial attempt to control disease without cytotoxic therapy, CsA/MMF were discontinued and rituximab (375 mg/m 2 , split on days +10 and +11) was administered. On day +11, the patient was intubated due to worsening respiratory insufficiency. Chemotherapy was then initiated with cyclophosphamide at 2 g/m 2 /day i.v. (days +11 and +12), paclitaxel at 250 mg/m 2 i.v. over 24 h (day +12), a second rituximab dose (day +13), and 6-methylprednisolone at 500 mg/day (from day +11). Prior to chemotherapy, there was evidence of neutrophil and platelet engraftment, and initial donor chimerism in granulocytes and mononuclear cells (MNC). The slowly plateauing drop in the lymphocyte count (Figure 1) , together with the unchanged pulmonary status prompted the addition of doxorubicin (50 mg/m 2 i.v.) on day +14. Chemotherapy was tolerated well without significant organ toxicity. Due to the prior finding of bronchial Aspergillus colonization, granulocyte transfusions were administered throughout the neutropenia period (Figure 1 ). Over the following days, marked clinical and radiological responses were observed. CsA was reinstituted, and the dose of steroids was rapidly tapered. The patient was extubated on day +33, and discharged to the outpatient clinic on day +49.
CsA was partially tapered from day +50, without evidence of GVHD. Neutrophils and platelets recovered on days +29 and +48, respectively (Figure 1) . Serial molecular DNA studies showed increasing donor chimerism in granulocytes, MNC, T lymphocytes and BM (Figure 2 ). The outpatient course was notable for a second episode of CLL progression, with rising LDH and progressive lymphadenopathy, which responded to DLI (10 7 CD3 + /kg) administered on day +99 under immunosuppressive cover using CsA/MMF, as described for the initial transplant, to day +371. On day +251, flow cytometry did not detect any monoclonal B cell population in the peripheral blood. At the time of reporting, 20 months after his NST, his CLL is in complete remission, by microscopy, flow cytometric and cytogenetic studies. The patient is off immunosuppressants and experiencing biopsy-proven asymptomatic grade 1 cutaneous GVHD, with 100% performance status. He remains on antimicrobial prophylaxis with levofloxacin, acyclovir and fluconazole.
Discussion
New approaches of NST rely on GVT reactions for antitumor effect. A potentially important problem in employing minimally intensive regimens for treatment of aggressive malignancies is that fatal tumor progression may occur before an effective immunologic response has developed. In contrast to our approach, others have used more intensive nonmyeloablative regimens for cytoreduction and immunosuppression. However, the clinical behavior of the CLL pretransplant did not suggest its early life-threatening, explosive pulmonary progression post-transplant, which prompted polychemotherapy, using cyclophosphamide, paclitaxel, doxorubicin and steroids. A dramatic tumor response, most closely associated with doxorubicin administration, was achieved without subsequent compromise of donor engraftment. DLI, rather than further taper of immunosuppression, was employed to treat subsequent progression, due to concerns about further rapid growth, and possible blunting of GVHD reactions by chemotherapy, as suggested by preclinical models. 4, 5 It was noticeable that the second time the tumor progressed after transplant, it exhibited a less aggressive clinical course, was charac-
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terized by an LDH rise with normal lymphocyte counts, and was effectively controlled by DLI.
The cytotoxic drugs used to treat this patient were selected because, to some degree, they spare hematopoietic stem cells. Paclitaxel/cyclophosphamide 6 and doxorubicin-containing regimens 7 have been successfully employed for stem cell mobilization. Likewise, administration of doxorubicin- 8 and paclitaxel-based 9 chemotherapy on days +38 and +30, respectively, after myeloablative autologous transplant has been associated with subsequent hematopoietic recovery. However, earlier use of chemotherapy, at doses high enough to induce a tumor response, has not been reported after allografting, and clearly might produce slowing or non-engraftment of donor stem cells. In a randomized trial that showed superiority of CsA/methotrexate over CsA for GVHD prophylaxis, the use of methotrexate at immunosuppressive doses caused an average 5-day delay in neutrophil engraftment. 10 In this case, the use of chemotherapy before engraftment effectively controlled explosive tumor progression without obviously compromising high level donor engraftment. The robust dose of CD34 + cells delivered may have been important in early hematopoietic recovery. While delivery of chemotherapy early after a myeloablative SCT to treat resistant disease might be of little use, its use after NST may facilitate subsequent use of DLI as reported here.
